GPP
RVNC

Great Point Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Great Point Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-300,000
Closed -$10.7M – 45
2017
Q4 		$10.7M Buy
+300,000
New +$8.62M 1.83% 23
2016
Q3 		– Sell
-21,665
Closed -$295K – 49
2016
Q2 		$295K Buy
+21,665
New +$383K 0.08% 35

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Great Point Partners's RVNC Position: Q1 2018 in Review

Great Point Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2018, closing a stake of 300,000 shares — an estimated $10.7M sold.

Great Point Partners first reported a position in RVNC in Q2 2016 and held it in 2 quarters. The position peaked at $10.7M in Q4 2017. 120 funds tracked by Wall St. Rank hold RVNC as of Q1 2018.

  • Great Point Partners reported no remaining Revance Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Great Point Partners sold 300,000 Revance Therapeutics, Inc. shares in Q1 2018, an estimated $10.7M.
  • Great Point Partners first reported a position in Revance Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • Great Point Partners's Revance Therapeutics, Inc. position peaked at $10.7M in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2018.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.